electroCore, Inc. (NASDAQ:ECOR – Get Free Report) Director Thomas Errico bought 10,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The stock was bought at an average price of $5.44 per share, with a total value of $54,400.00. Following the completion of the purchase, the director directly owned 373,904 shares in the company, valued at $2,034,037.76. This represents a 2.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
electroCore Trading Down 7.8%
Shares of NASDAQ ECOR opened at $4.84 on Tuesday. The stock has a market cap of $44.67 million, a price-to-earnings ratio of -3.48 and a beta of 1.23. electroCore, Inc. has a 12 month low of $4.37 and a 12 month high of $12.70. The company has a 50 day simple moving average of $8.92 and a two-hundred day simple moving average of $7.72.
electroCore (NASDAQ:ECOR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.14. The company had revenue of $9.69 million for the quarter, compared to analysts’ expectations of $10.93 million. Analysts forecast that electroCore, Inc. will post -1.17 EPS for the current year.
Hedge Funds Weigh In On electroCore
An institutional investor recently bought a new stake in electroCore stock. Cetera Investment Advisers acquired a new stake in electroCore, Inc. (NASDAQ:ECOR – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 32,950 shares of the company’s stock, valued at approximately $357,000. Cetera Investment Advisers owned about 0.36% of electroCore at the end of the most recent quarter. 26.74% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $18.00.
Check Out Our Latest Report on electroCore
About electroCore
electroCore is a medical technology company that develops non-invasive bioelectronic therapies. Its products use non-invasive vagus nerve stimulation (nVNS), which delivers gentle electrical stimulation through the skin to activate the vagus nerve. The company’s gammaCore device is used for the treatment of certain headache conditions, including migraine and cluster headache, subject to its regulatory clearances and indications. electroCore also offers Truvaga, a consumer wellness product that uses non-invasive vagus nerve stimulation.
See Also
- Five stocks we like better than electroCore
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
